Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T20:02:40.115Z.
Calculation as of: 2026-10-06T20:02:40.115Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6a3e1feeb410069f07e4350e21f058018b4d4b1a35d97054c3a706da9d6a2f8d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Humacyte, Inc.
Market Cap
$80.30M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| Humacyte, Inc. (HUMA) | $80.30M | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $80.80M | N/A |
| Nutriband Inc. (NTRB)vs › | $81.63M | N/A |
| vTv Therapeutics Inc. (VTVT)vs › | $78.18M | N/A |
| LENSAR Inc (LNSR)vs › | $82.29M | N/A |
| MediciNova, Inc. (MNOV)vs › | $81.22M | N/A |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $82.43M | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $82.47M | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
